Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2023 Jun 19;27(1):161. doi: 10.1038/s41391-023-00681-3

Correction to: ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis

Ronald Tutrone 1,, Ben Lowentritt 1, Brian Neuman 1, Michael J Donovan 2, Elliot Hallmark 3, T Jeffrey Cole 3, Yiyuan Yao 3, Claire Biesecker 1, Sonia Kumar 3, Vinita Verma 3, Grannum R Sant 3,4, Jason Alter 3, Johan Skog 3
PMCID: PMC10876471  PMID: 37337052

Correction to: Prostate Cancer and Prostatic Diseases 10.1038/s41391-023-00675-1, published online 16 May 2023

The final sentence in the Results section of the abstract should read:

At 2.5 years, patients with low-risk EPI scores from both arms had less HGPC than high-risk EPI score patients (7.9% vs 27.3%, p < 0.001) and the EPI arm found 21.8% more HGPC than the SOC arm.

Instead, the final sentence in the Results section of the abstract currently reads:

At 2.5 years, patients with low-risk EPI scores from both arms had less HGPC than high-risk EPI score patients (7.9% vs 26.8%, p < 0.001) and the EPI arm found 18% more HGPC than the SOC arm.

The original article has been corrected.


Articles from Prostate Cancer and Prostatic Diseases are provided here courtesy of Nature Publishing Group

RESOURCES